I hope you're right. I got time to read INSM / Bunslow's final brief and found it to be quite compelling. I especially liked the parts where he pointed out INSM is the one with all the investments in IGF science and how DNA never developed BP3 but now want to stifle it's innovation / benefits.
However I don't think it's likely Wilken will override the jury on all counts. I do not believe that an injunction is imminent, but when it comes to the legal system it's a crapshoot. I do like our odds better with a circuit court of appeals 3 judge panel than a CA DNA home turf jury.
Market Data 
Markets 
AI
